The market came into Gushengtang Holdings’ half year results in a cautiously positive mood, with the stock roughly flat over the past month and modestly higher over three months. The headline this time is earnings power. Net income for H1 2026 reached C¥220.7m and basic earnings per share hit C¥1.0, which keeps profit growth ahead of the revenue line in this traditional Chinese medicine healthcare business.
Trailing earnings tell a similar story. Over the past 12 months, earnings grew about 20% and net margin sits near 12.4%. That combination underpins a P/E of 12.7x that appears undemanding compared with Hong Kong healthcare peers.
Impressed by Gushengtang Holdings’ earnings power and margin profile but want a broader set of healthcare stocks with similar value credentials and balance sheet strength? Take a look at our hand picked list of solid balance sheet and fundamentals stocks (426 results).
H1 2026 Earnings Summary
- Revenue (H1 2026 vs. H1 2025): C¥1,652.9m vs. C¥1,494.9m (up about 11%)
- Net Income excluding extra items (H1 2026 vs. H1 2025): C¥220.7m vs. C¥151.6m (up about 46%)
- Basic EPS (H1 2026 vs. H1 2025): C¥1.00 vs. C¥0.63 (up about 58%)
- Trailing 12 month net profit margin (H1 2026 vs. prior year): 12.4% vs. 11.2% (improved margin profile)
Tired of scrolling through walls of earnings tables and raw figures on Gushengtang Holdings? Get a clear visual snapshot of the company’s overall valuation and financial picture in the company report for Gushengtang Holdings..
Gushengtang bullish case, earnings momentum and defensiveness
For investors leaning positive on Gushengtang Holdings, the latest half year shows earnings power running ahead of revenue. Revenue for H1 2026 is higher than H1 2025, yet net income excluding extra items and basic EPS grow more quickly. This fits a healthcare platform improving its economics as it scales. Trailing 12 month net margin of 12.4% compared with 11.2% a year earlier supports the idea that the traditional Chinese medicine clinic and supply chain model can convert demand into healthier profitability, not just top line size.
Gushengtang bearish case, execution and quality questions
Bears focused on execution risk in Gushengtang still have questions, although these numbers soften some of the immediate concerns. The business spans offline clinics, online services and pharmaceutical wholesale, which can dilute profitability, yet margins have improved on a trailing basis. That reduces the near term force of arguments around structurally weak economics. However, the share price has moved only modestly over 30 and 90 days. This suggests investors are still weighing regulatory exposure and the complexity of scaling a wider TCM network before assigning a stronger view.
Compare Gushengtang Holdings’ improving margins and EPS momentum with how the market is actually pricing SEHK:2273 after the H1 2026 release. See the consensus price target analysis for Gushengtang Holdings to check whether analysts think the earnings story justifies a different share price path.Stay Ahead With Simply Wall St
If Gushengtang Holdings’ improving margins and EPS momentum caught your eye, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and spot an entry point that fits your plan. Once you have a position, use the Portfolio Command Center to cut through noise and focus on essential updates that matter to your holdings. For longer term conviction, tap into the Community to see how other investors are thinking about the same risks and opportunities. This way you can surface hidden catalysts or early warning signs sooner and stay ahead of the market.
Seeking Alternatives Beyond Gushengtang Holdings?
Fresh stock ideas can pick up momentum fast and move before most investors even react. Scan these curated shortlists while they are still under the radar for now and act now.
- Spot potential breakout compounders early by scanning our curated list of quality companies with resilient balance sheets in the list of solid balance sheet and fundamentals stocks (426 results).
- Ride long term themes with stocks linked to cryptocurrency and blockchain adoption before attention spikes by reviewing the hand picked 19 cryptocurrency and blockchain stocks.
- Target income opportunities that aim to keep cash flows flying while prices drop in and out of favour by checking the curated 417 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com